Enarodustat

Enarodustat
Clinical data
Trade namesEnaroy
Other namesJTZ-951
Legal status
Legal status
  • Rx-only (Japan)
Identifiers
  • 2-{[7-Hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]formamido}acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H16N4O4
Molar mass340.339 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
  • InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24)
  • Key:FJYRBJKWDXVHHO-UHFFFAOYSA-N

Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH).

The drug was approved in September 2020 in Japan for anemia associated with CKD and is currently in clinical development in the United States and South Korea. The drug is being developed by Japan Tobacco and JW Pharmaceutical.